The FDA on December 2, 2021, approved RITUXAN® in combination with chemotherapy for pediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive Diffuse Large B-Cell Lymphoma (DLBCL), Burkitt Lymphoma, Burkitt-Like Lymphoma, or mature B-cell Acute leukemia. RITUXAN® is a product of Genentech, Inc.
Bottom Ad
Advertisement
Subscribe
